This is (supposed to be) a reflective diary by a (not very) anonymous biomedical scientist who works somewhere in the south of England.
One day this diary may well be submitted to the Health and Care Professions Council as evidence of ongoing continual professional development....
this retrospective review of 946 patients, the authors investigate the
effectiveness of accelerated partial breast irradiation for select
patients with invasive breast cancer and determined that patients deemed
unsuitable for this treatment by criteria established by the American
Brachytherapy Society or the American Society for Radiation Oncology
were not at increased risk for ipsilateral breast tumor recurrence.
combination of anlotinib and S-1 exhibited good antitumor activity in
third- or later-line treatment for stage IV non-small cell lung cancer
Combination therapy of anlotinib with S-1 has manageable toxicities in patients with NSCLC.
Jose Baselga, MD, PhD, Young Investigator Award in Drug Development
Cancer, the ASCO Foundation, is soliciting applications for the Jose
Baselga, MD, PhD, Young Investigator Award in Drug Development. It’s a
one-year $60,000 research grant ($50k to the investigator and $10k to
the mentor). For complete eligibility information and application
instructions, download the Jose Baselga, MD, PhD, Young Investigator Award in Drug Development RFP. The application deadline is January 10, 2022.
Applicants with questions about this award can reach out to Conquer Cancer by email at firstname.lastname@example.org.